News Breaks |
|
|
| November 20, 2012 |
| 19:35 EDT |  | NVS | Novartis attractive for patient investors, Barron's says
Citing a promising pipeline of drugs and a 4% dividend, a Barron's report says that investors willing to buy and hold shares of Novartis (NVS) into next year will be poised for gains. The report notes that 30% of the company's sales come from drugs that have come to market since 2007, and attributes this to the company's commitment to research and development, another element that adds to the stock's long-term attractiveness. Shares of Novartis traded fractionally lower on today's session, down 40c, or 0.67%, to $59.09. Reference Link |
|
|
News For NVS From The Last 14 Days Check below for free stories on NVS the last two weeks. |
|
|
| May 21, 2013 |
| 07:44 EDT |  | NVS | Sachs Associates to host a forum
 Subscribe for More Information |
|
| 07:24 EDT | | NVS | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 07:29 EDT | | NVS | Deutsche Bank to host a conference
dbAccess Asia Conference 2013 is being held in Singapore on May 20-22. |
|
| May 17, 2013 |
| 16:20 EDT |  | NVS | Novartis drug Afinitor extended time without disease progression in women
Subscribe for More Information |
|
| May 16, 2013 |
| 08:11 EDT | | NVS | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT | | NVS | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 18:17 EDT | | NVS | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information |
|
| May 10, 2013 |
| 05:42 EDT | | NVS | Novartis drug Ilaris approved by FDA
Subscribe for More Information |
|
|
|
|
|
